Vaccine

• Un estudio reciente demuestra que una formulación de vacuna actualizada redujo las visitas a los departamentos de urgencias y las hospitalizaciones entre adultos sanos en aproximadamente un 50 por ciento durante la temporada pasada. • Esta mejora significativa de la eficacia representa un avance importante en el desarrollo de vacunas y en las estrategias de protección de la salud pública. • Los hallazgos contribuyen al panorama en evolución de la política de vacunas de U.S., tal como se documenta en el último informe sobre el estado de la política de vacunas de CIDRAP del 28 de abril de 2026.

• A multiyear international campaign is underway to repair damage to childhood immunization efforts caused by the COVID-19 pandemic. • The initiative focuses on restoring vaccination rates that declined during the pandemic period across multiple countries. • Public health experts view this effort as critical to preventing resurgence of vaccine-preventable diseases in vulnerable pediatric populations.

• Health Secretary Robert F. Kennedy Jr., a prominent anti-vaccine voice, praised President Trump's nomination of Dr. Erica Schwartz as CDC Director and expressed his intention to work with her to restore the agency's mission. • Kennedy's public endorsement of the pro-vaccine nominee marked a sharp reversal from his previously hard-line stance on CDC leadership and sparked significant backlash among MAHA (Make America Healthy Again) loyalists online. • The shift comes amid congressional scrutiny of Kennedy's conflicting rhetoric on measles vaccination safety during a Thursday hearing, as measles outbreaks rise across the U.S.

Several shots – including flu and Covid – lost their CDC recommendations under overhauls from the White HouseSeveral shots lost their recommendation from the US Centers for Disease Control and Prevention (CDC) after a judge’s stay against changes wrought by the Trump administration – which may affect access to the shots in some states. And no new vaccine recommendations may be made as long as the vaccines committee is halted.Access to existing vaccines – and the future development of new vaccines – has been increasingly called into question under the second Trump administration, as the now-halted Advisory Committee on Immunization Practices (ACIP) made controversial recommendations and health officials made unilateral changes to routine vaccines, with long-term and global implications. Continue reading...

• A Fred Hutch Cancer Center graduate student presented over 25,000 measurements of influenza-fighting antibodies to WHO scientists via videoconference last fall. • The dataset, published in Virus Evolution, offers near real-time tracking of human immune responses to current flu strains, improving seasonal vaccine composition. • This method addresses gaps in traditional surveillance, potentially enhancing vaccine effectiveness against evolving viruses.

Study that reportedly found reduction in ER visits and hospitalizations being reviewed by Jay BhattacharyaA Trump administration appointee has delayed publication of a Centers for Disease Control and Prevention (CDC) report that shows benefits related to the Covid vaccine, leading to concerns that the administration is engaging in behind-the-scenes tactics to undermine vaccines.Research by CDC scientists found that the Covid vaccine cut the likelihood of emergency room visits and hospitalizations for healthy adults last winter by about half, according to reporting from the Washington Post. The acting CDC director, Jay Bhattacharya, reportedly delayed the report’s publication due to concerns surrounding the research’s methodology. Continue reading...

• The FDA granted approval on April 7, 2026, to Moderna's mRESVIA vaccine, an mRNA-based shot targeting respiratory syncytial virus (RSV) for adults aged 60 and older. • Clinical trials showed 83.7% efficacy against RSV lower respiratory tract disease in the first season, with data from over 37,000 participants across 22 countries including US sites. • This marks the second mRNA RSV vaccine approved after GSK's Arexvy, aiming to reduce 140,000-160,000 annual US hospitalizations among seniors; CDC review expected soon.